

Figure S1 PRISMA flow-chart summarizing the search strategy for relevant publications.

Table S1 Postoperative drug protocols		
Primary author	Antiarrhythmic drug	Anticoagulation
Ad <i>et al.</i> (18)	Amiodarone for 3 months, stopped if in SR	Warfarin (INR 2-2.5) for 6 months, stopped if in SR/No LAA excluded on TTE
Baek <i>et al.</i> (19)	Amiodarone for 3 months, stopped if in SR	Anticoagulation (not specified) for 3-6 months. Aspirin 100mg/day after
Bando <i>et al.</i> (20)	Digoxin	Warfarin
Bogachev-Prokophiev <i>et al.</i> (21)	Amiodarone 200mg/day for 3 months, stopped if in SR	Warfarin (lifetime for mechanical, 6 months for biological)
Brick <i>et al.</i> (22)	Amiodarone 200mg/day for 6 months	Not Specified
Chavez <i>et al.</i> (23)	Not Specified	Not Specified
Chen <i>et al.</i> (24)	Amiodarone 200 mg once daily for 3-6 months	Not Specified
Churyla <i>et al.</i> (25)	Not Specified	Warfarin
Dong <i>et al.</i> (26)	Amiodarone 200mg/day for 3 months, stopped if in SR	Warfarin (INR 1.5-2)
Ezelsoy <i>et al.</i> (27)	Amiodarone 200 mg and metoprolol 50 mg per oral for 3 months	Warfarin for 3 months
Funatsu <i>et al.</i> (28)	Unspecified class 1a or 1c AADs	Warfarin (lifetime for mechanical, 3 months for biological)
Garcia-Villarreal (29)	Amiodarone 200mg/day for 3 months, stopped if in SR	Not specified
Gatti <i>et al.</i> (30)	Amiodarone 200 or 400mg/day until SR	Warfarin 3-6 months with INR 2.0-3.0
Geidel <i>et al.</i> (31)	Amiodarone 200mg daily for 3 months	Warfarin (lifetime for mechanical, 3 months for biological)
Gelsomino <i>et al.</i> (32)	Amiodarone 200mg BD for 1 week, then 200mg daily for 6 months	Warfarin for 6 months, INR target of 2.5-3.5
Gillinov <i>et al.</i> 2006 (33)	Not Standardized	Not Standardized
Gillinov <i>et al.</i> 2015 (11)	Not Standardized	Not Standardized
Goette <i>et al.</i> (34)	Amiodarone 400mg for 48 hours	Anticoagulation for 3 months
Han <i>et al.</i> (35)	Amiodarone 200mg daily for 3 months	Warfarin for 6 months, INR 2-2.5
Hwang <i>et al.</i> (26)	Not standardized	Warfarin 3-6 months with INR 1.5-2.5
Jiang <i>et al.</i> (37)	Amiodarone 200mg TDS 1 week, BD 1 week, daily until 3 months. If not in SR, then continued to 6 months	Not Specified
Kasemsarn <i>et al.</i> (38)	Amiodarone for 6 months	Warfarin for 1 year and aspirin for life if Holter monitor proved no AF.
Kim (39)	Not Specified	Not Specified
Kim <i>et al.</i> (40)	Not Specified	Warfarin with INR 2-3 (mechanical). Warfarin 3-6 months with INR 1.5-2.5 (bioprosthetic)
Labin <i>et al.</i> (41)	Class I/III AADs, for 2 months	Warfarin 3-6 months
Lavalle <i>et al.</i> (42)	Amiodarone 200mg TDS 1 week, BD 1 week, daily until SR	Warfarin
Lawrence <i>et al.</i> (43)	Class I/III AADs, for 2 months	Warfarin
Loardi <i>et al.</i> (44)	Amiodarone 200mg TDS until discharge, then 200mg daily for 6 months	Not specified
McCarthy <i>et al.</i> (45)	Not Specified	Not specified
Nardi <i>et al.</i> (46)	Amiodarone 200mg daily 4-6wks. After this, 200mg daily for 5 days per week until SR	Warfarin 3 months, INR 2.5-3.5
Rahmanian <i>et al.</i> (47)	Amiodarone given at cardiologist's discretion	Warfarin lifelong (mechanical), 2 months (bioprosthetic)
Rostagno <i>et al.</i> (48)	Amiodarone 200mg BD until discharge, then 200mg daily for 3 months	Warfarin lifelong (mechanical), 6 months (bioprosthetic) INR 2.5-3.5
Wang <i>et al.</i> (49)	Amiodarone 3 months	Warfarin 3 months, INR 2-2.5
Wang <i>et al.</i> (50)	Amiodarone (dose not specified)	Warfarin 3 months for pts with LA diameter >50mm
Wu <i>et al.</i> (51)	AADs not used	Heparin 2 weeks, warfarin for 6 weeks
Yao <i>et al.</i> (52)	Amiodarone 200mg daily for 3 months	Warfarin




Figure S2 Postoperative stroke.




Figure S3 Postoperative re-exploration.




Figure S4 Postoperative PPM insertion.






Figure S5 Leave one out analysis.



**Figure S6** Funnel plot for freedom from AF.



**Figure S7** Funnel plot for mortality.

Study	Risk of bias domains							Overall
	D1	D2	D3	D4	D5	D6	D7	
Ad et al	+	+	-	-	-	+	+	+
Baek et al	-	-	-	+	+	+	+	-
Bando et al	-	-	-	+	-	-	X	-
Bogachev-Prokophiev et al	-	-	+	+	-	+	+	-
Brick et al	+	-	+	-	-	-	-	-
Chavez et al	-	-	X	-	-	-	-	-
Chen et al	-	-	+	+	-	+	-	-
Churyla et al	-	-	+	-	-	-	-	-
Dong et al	-	-	+	+	-	-	-	-
Ezelsoy et al	-	X	-	+	+	-	-	X
Funatsu et al	-	-	-	+	+	X	-	-
Garcia-Villarreal	-	-	-	-	+	-	-	-
Gatti et al	-	-	-	+	-	+	-	-
Geidel et al	+	-	-	+	+	X	-	-
Gelsomino et al	-	-	-	-	-	X	-	-
Gillinov et al 2006	-	-	X	-	+	+	-	-
Goette et al	+	+	-	-	X	+	-	-
Hwang et al	-	X	-	-	+	-	-	-
Jiang et al	-	-	-	-	-	X	-	X
Kasemsarn et al	-	-	-	-	-	-	X	-
Kim KC	-	-	-	X	-	+	+	-
Kim W.K et al	-	-	-	-	+	-	X	-
Labin et al	-	-	+	-	-	-	+	+
Lavalle et al	-	-	-	X	-	-	-	X
Lawrence et al	-	X	-	-	X	-	-	X
Loardi et al	-	-	-	+	-	+	-	-
McCarthy et al	-	-	-	+	+	+	-	+
Nardi et al	-	X	X	X	-	-	-	X
Rahmanian et al	-	-	-	-	-	X	-	-
Rostagno et al	-	+	-	-	+	-	-	+
Wang H et al	-	-	-	+	-	+	-	-
Wang et al	-	X	-	-	-	-	-	-
Wu et al	-	-	-	-	+	-	-	-
Yao et al	-	-	-	+	-	-	-	-

Domains:  
D1: Bias due to confounding.  
D2: Bias due to selection of participants.  
D3: Bias in classification of interventions.  
D4: Bias due to deviations from intended interventions.  
D5: Bias due to missing data.  
D6: Bias in measurement of outcomes.  
D7: Bias in selection of the reported result.

Judgement  
X Serious  
- Moderate  
+ Low

Figure S8 Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I).



Study	Risk of bias domains					Overall
	D1	D2	D3	D4	D5	
Gillinov et al 2015	+	+	-	+	+	+
Han et al	+	+	+	-	-	-

Domains:  
D1: Bias arising from the randomization process.  
D2: Bias due to deviations from intended intervention.  
D3: Bias due to missing outcome data.  
D4: Bias in measurement of the outcome.  
D5: Bias in selection of the reported result.

Judgement  
- Some concerns  
+ Low

**Figure S9** Risk of Bias in Randomised Trials (RoB2).